Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

Vantaggiato, Lorenza; Perruzza, Marco; Refini, Rosa Metella; Bergantini, Laura; d’Alessandro, Miriana; Cameli, Paolo; Perruzza, Davide; Bini, Luca; Bargagli, Elena; Landi, Claudia

doi:10.1007/s00408-020-00379-6

Cited by 14 publications

(14 citation statements)

References 14 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 Our data also support observations by recent smaller studies focused on the clinical outcomes and underlying immunological changes following anti-IL5 or anti-IL5Rα therapy. 7,[25][26][27][28] However, our findings stand in contrast to the indirect comparison performed by Busse et al, who had seen an advantage for mepolizumab in terms of asthma control and reduction of exacerbations. 17 It is important to note, however, that Bourdin et al, Cabon et al, and Busse et al re-analyzed existing phase-3 drug trial data by using the respective control groups as references to perform an indirect comparison between treatment groups.…”

Section: Discussioncontrasting

confidence: 99%

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Kayser

Drick

Milger

et al. 2021

JAA

View full text Add to dashboard Cite

Purpose: Treatment of severe eosinophilic asthma (SEA) has been revolutionized by the development of monoclonal antibodies targeting underlying immunological pathways of eosinophilic asthma. Two of the most frequently used antibodies in clinical practice are mepolizumab, targeting interleukin (IL) 5 and benralizumab, targeting the IL5 receptor alpha. The comparative treatment efficacy of these antibodies remains unclear, particularly regarding long-term outcomes. Patients and Methods: In this multicenter, retrospective study, we included 123 patients treated with mepolizumab and 64 patients treated with benralizumab for 12 months at one of three study sites in Germany. Data were collected at baseline and after 6 and 12 months of therapy. Endpoints were changes in pulmonary function (PF), exacerbation rate, oral corticosteroid (OCS) use and dose, asthma control test (ACT) score and fractional exhaled nitric oxide (FeNO) levels. Results: Both mepolizumab and benralizumab led to significant improvements in PF with an increase in median forced expiratory volume (FEV1) after 12 months from 59% to 74% for mepolizumab and 63% to 72% for benralizumab. Treatment also led to significant improvements in ACT scores after 12 months (mepolizumab: 13 [interquartile range (IQR) 9-17] to 19 to 22 ) as well as a reduction of mean OCS dose (mepolizumab 8 mg [IQR 5-12.5 mg] median prednisolone equivalent at baseline to 5 mg [IQR 3-7.5 mg]; benralizumab 7.5 mg to 5 mg [IQR 2-10 mg]). The exacerbation rates were reduced significantly, irrespective of the treatment. Overall, changes were similar after 6 and 12 months of therapy. Conclusion: Both mepolizumab and benralizumab are highly effective in the long-term treatment of SEA, with no clinically relevant differences in outcomes after 12 months of therapy. In both groups, improvements were similar after 6 and 12 months of therapy, underlining the feasibility of early treatment evaluation.

show abstract

Section: Discussioncontrasting

confidence: 99%

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Kayser

Drick

Milger

et al. 2021

JAA

View full text Add to dashboard Cite

show abstract

“…Severe eosinophilic asthma (SEA) is a heterogeneous condition characterized by uncontrolled symptoms, such as intermittent dyspnoea, wheezing, dry cough and poor response to maximum doses of corticosteroids 1,2,34,35 . Effective asthma therapy is important for public health, as SEA has high social impacts and impairs quality of life 3,33,36 . The pathogenic mechanisms of SEA are associated with a type 2 (Th2) inflammatory response followed by release of inflammatory cytokines, including interleukin‐5 (IL‐5), responsible for eosinophil proliferation, activation 3,4 …”

Section: Introductionmentioning

confidence: 99%

“…1,2,34,35 Effective asthma therapy is important for public health, as SEA has high social impacts and impairs quality of life. 3,33,36 The pathogenic mechanisms of SEA are associated with a type 2 (Th2) inflammatory response followed by release of inflammatory cytokines, including interleukin-5 (IL-5), responsible for eosinophil proliferation, activation. 3,4 Regulatory T cells have been shown to play a crucial role in the development of asthma.…”

Section: Introductionmentioning

confidence: 99%

Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab

et al. 2021

Self Cite

View full text Add to dashboard Cite

Severe eosinophilic asthma (SEA) has been associated with T‐helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for severe cases. Mepolizumab, an IL‐5 antagonist, is indicated for the treatment of severe asthma. Regulatory T cells (Tregs) suppress inflammation by secreting cytokines that inhibit Th2 cell proliferation. We investigated peripheral Treg, CD4, CD8, CD19 and NK cell percentages and their relationship to clinical and functional parameters, including peripheral eosinophils, before and after anti‐IL5 treatment. Subjects were 14 adult SEA patients (9 male, 54.1 ± 11.6 years), treated with mepolizumab, and 10 controls. T cells (CD4 and CD8), CD19, NK and Tregs were evaluated by flow cytometry. Comparison of lung function parameters before and after treatment with mepolizumab (T0 and T1) showed an increase in FEV1, FEV1/FVC ratio and a reduction in blood eosinophil percentages. CD8 and CD16/56+CD3+ were significantly higher in SEA patients than controls (P = .04 and P = .03, respectively). A decrease in CD45+, CD8 + and CD16/56+CD3+ cell percentages was observed between T0 and T1 (P = .02, P = .04, P = .03, respectively). A significant increase in Treg percentages (P = .0001) was recorded between T0 and T1. Mepolizumab therapy was found to modulate immune response, restoring immune balance in patients with SEA.

show abstract

“…14 Mepolizumab is a humanized monoclonal antibody that affects the IL-5α-chain and prevents its binding to the α subunit of the IL-5 receptor. 15 On the other hand, benralizumab binds to the IL-5Rα subunit expressed on eosinophils, enhancing antibody-dependent cellular cytotoxicity and reducing circulating levels of eosinophils. 16 Importantly, these anti-IL-5 agents have been in focus as alternative treatments for ICEP patients with frequent relapses on corticosteroid treatment.…”

Section: Introductionmentioning

confidence: 99%

Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series

Tashiro¹,

Takahashi²,

Kurihara³

et al. 2022

JAA

View full text Add to dashboard Cite

Idiopathic chronic eosinophilic pneumonia (ICEP) is a rare, chronic respiratory disease. Corticosteroid therapy is effective for ICEP, but relapse is frequent after its tapering, which leads to chronic use and corticosteroid-related adverse effects. Currently, biological agents targeting interleukin 5 (IL-5) are considered alternatives for treating ICEP patients with frequent relapse, but the detailed effects are not fully understood. Patients and Methods: The clinical characteristics of 30 patients with ICEP, especially 12 patients with ICEP who experienced relapse after corticosteroid dose tapering, were evaluated retrospectively. In addition, 4 ICEP patients with frequent relapse treated by IL-5-targeted biological agents were reviewed. Results: Of the 30 patients diagnosed with ICEP, 12 patients (40.0%) recurred after corticosteroid dose tapering, and 9 (30.0%) were treated with maintenance doses of corticosteroid. Of ICEP patients who experienced recurrence, 6 (50.0%) had frequent relapses (2 or more times). All 4 patients treated with anti-IL-5 agents had their corticosteroid dose reduced without any relapses; in 3 patients, corticosteroids were withdrawn. Conclusion: Anti-IL-5 agents might be alternatives for treating ICEP patients with frequent relapses.

show abstract

Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

Cited by 14 publications

References 14 publications

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months

Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab

Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series

Contact Info

Product

Resources

About